New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 5, 2013
11:59 EDTTHC, CYH, LLY, PFE, BMYObama to propose cutting Medicare payments to companies, The Hill says
The budget proposal that President Obama is set to unveil next week would cut payments from Medicare to "healt care providers and pharmaceutical companies," according to The Hill. The proposal could affect the revenue of large hospitals such as Tenet Healthcare (THC) and Community Health (CYH), and major drug makers such as Eli Lilly (LLY), Pfizer (PFE), and Bristol Myers (BMY). GOP House Speaker John Boehner criticized the proposal because it includes tax increases, the website noted. Reference Link
News For THC;CYH;LLY;PFE;BMY From The Last 14 Days
Check below for free stories on THC;CYH;LLY;PFE;BMY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
August 26, 2014
09:07 EDTLLYEli Lilly announces Jardiance available in U.S. pharmacies
Subscribe for More Information
08:01 EDTPFEPfizer, Merck to collaborate on study evaluating anti-cancer combination regimen
Subscribe for More Information
August 25, 2014
10:54 EDTTHCHigh option volume stocks
Subscribe for More Information
07:59 EDTCYHSome healthcare providers offer compelling opportunities, says Jefferies
Jefferies believes that the following healthcare providers reported good Q2 results which have not been adequately reflected by their stocks: Acadia Healthcare (ACHC), Almost Family (AFAM), Brookdale Senior Living (BKD), Catamaran (CTRX), Community Health (CYH), Envision Healthcare (EVHC), and HCA Holdings (HCA). The firm expects the sector as a whole to continue to improve in 2H14 amid continued tailwinds from healthcare reform.
06:29 EDTPFEPfizer mulls possible AstraZeneca offer options, FT says
Subscribe for More Information
August 22, 2014
14:19 EDTPFEViiV Healthcare receives FDA approval for HIV-1 treatment Triumeq
Subscribe for More Information
12:39 EDTBMYThese five companies will benefit from increased ALS awareness, MarketWatch says
A recent surge in funding for Lou Gehrig's disease, or ALS, caused by the Ice Bucket challenge that is widespread on social media outlets, will benefit five pharmaceutical companies that are involved in the development of a cure for ALS, according to MarketWatch. The companies that are or have been involved in developing a treatment for ALS include Biogen Idec (BIIB), Avanir Pharmaceuticals (AVNR), Isis Pharmaceuticals (ISIS), Sanofi (SNY), and Bristol-Myers Squibb (BMY), MarketWatch added. Reference Link
August 21, 2014
13:32 EDTBMY, PFEBristol-Myers, Pfizer announce approval of Eliquis for treatment of DVT, PE
Subscribe for More Information
09:54 EDTPFEPotential Pfizer, AstraZeneca deal seen around year-end, Reuters says
Investors and analysts see Pfizer (PFE) making another attempt to acquire AstraZeneca (AZN) around year-end, even though talks between the two can resume on August 26 per British takeover rules, Reuters reports. Reference Link
08:02 EDTPFEPfizer initiates U.S. EAP for palbociclib.
Pfizer announced that the company has initiated a multi-center, open-label expanded access program in the U.S. for palbociclib. Through the program, palbociclib is being made available for use in combination with letrozole for post-menopausal women with hormone receptor positive human epidermal growth factor receptor 2 negative advanced breast cancer for whom letrozole is considered appropriate therapy.
07:55 EDTPFEActavis volatility expected to move on Pfizer considering new target report
Actavis (ACT) volatility is expected to move on Pfizer (PFE) considering other overseas alternatives, Bloomberg reports. Overall option implied volatility of 27 is near its 26-week average of 31 according to Track Data, suggesting decreasing price movement.
07:47 EDTPFEPfizer looking at new targets, including Actavis, Bloomberg reports
While it weighs another attempt to acquire AstraZeneca (AZN), Pfizer is considering other overseas alternatives, including Actavis (ACT), Bloomberg reports, citing people familiar with the matter. Pfizer prefers to reach a deal with AstraZeneca, and a move on another company is unlikely "anytime soon," Bloomberg adds, citing its sources. Shares of Actavis are rising 3%, or $6.65, to $230.01 in pre-market trading, while AstraZeneca is up 2% to $72.59. Reference Link
07:12 EDTLLYEli Lilly announces results from pivotal UNCOVER studies for ixekizumab
Eli Lilly announces that its investigational medicine ixekizumab was statistically superior to etanercept and placebo on all skin clearance measures in Phase 3 studies. Patients treated with both dosing regimens of ixekizumab had significantly greater levels of skin clearance compared to placebo and to etanercept at the 12-week endpoint. Skin clearance was measured by standard primary endpoints for psoriasis studies: the Psoriasis Area and Severity Index and the Static Physician Global Assessment. For patients treated with ixekizumab either every four weeks or every two weeks, between 78 to 90 percent of patients achieved at least a 75 percent reduction in PASI score at 12 weeks. Additionally, 31 to 41 percent of these patients achieved PASI 100, or clear skin, at week 12. For comparison, between 5 to 7 percent of patients treated with etanercept in the UNCOVER-2 and 3 studies achieved PASI 100. Adverse events were comparable for patients receiving ixekizumab in the 12-week, randomized control portion across all three studies.
August 20, 2014
08:03 EDTPFE, BMYBristol-Myers Pfizer to present new Eliquis data
Subscribe for More Information
08:02 EDTBMYBristol-Myers, Celgene enter collaboration agreement for OPDIVO, ABRAXANE
Subscribe for More Information
August 18, 2014
17:37 EDTLLYFDA grants tentative approval for Lilly, Boehringer Basaglar insulin
Subscribe for More Information
11:41 EDTPFE, LLYCubist rises after report sparks takeover interest speculation
Subscribe for More Information
10:41 EDTCYHCommunity Health discloses personal data compromised in cyber attack
Earlier today, Community Health (CYH) disclosed in a filing that in July Community Health Systems confirmed that its computer network was the target of an external, criminal cyber attack that the company believes occurred in April and June. The company and its forensic expert, Mandiant, a FireEye company (FEYE), believe the attacker was an “Advanced Persistent Threat” group originating from China who used highly sophisticated malware and technology to attack the company’s systems.The company has been informed by federal authorities and Mandiant that this intruder has typically sought valuable intellectual property, such as medical device and equipment development data. However, in this instance the data transferred was non-medical patient identification data related to the company’s physician practice operations and affected approximately 4.5M individuals who, in the last five years, were referred for or received services from physicians affiliated with the company. The company has confirmed that this data did not include patient credit card, medical or clinical information; the data is, however, considered protected under the Health Insurance Portability and Accountability Act because it includes patient names, addresses, birthdates, telephone numbers and social security numbers. The company does not believe this incident will have a material adverse effect on its business or financial results.
08:01 EDTPFEPfizer announces submission of Palbociclib NDA to FDA
Pfizer announced it has completed the submission of a New Drug Application to the United States Food and Drug Administration for palbociclib. This NDA requests FDA approval of palbociclib, in combination with letrozole, for the treatment of postmenopausal women with estrogen receptor positive, human epidermal growth factor receptor 2 negative advanced breast cancer who have not received previous systemic treatment for their advanced disease. The submission is based on the final results of PALOMA-1, a randomized, Phase 2 trial comparing palbociclib plus letrozole versus letrozole alone in this population of patients. Palbociclib received Breakthrough Therapy designation from the FDA in April 2013, for the first-line systemic treatment of women with advanced or metastatic ER+, HER2- breast cancer. This designation was based on interim data from the PALOMA-1 trial. The FDA has a 60-day filing review period to determine whether the NDA is complete and acceptable for filing. Pfizer will communicate the Agency’s decision.
07:57 EDTPFE, BMYCambridge Healthtech Institute to hold a summit
6th Annual Bioprocessing Summit to be held in Boston on August 18-22.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use